Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor

Use of biomarkers in identifying cancer patients that will be responsive to treatment with a PRMT5 inhibitor

US Patent 11279970 · Granted Mar 22, 2022

Estimated economic value: $293,223,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Spirobicyclic analogues2024
Use of biomarkers in identifying cancer patients that will be responsive to trea2024
Use of biomarkers in identifying cancer patients that will be responsive to trea2024
Use of biomarkers in identifying cancer patients that will be responsive to trea2024
Use of biomarkers in identifying cancer patients that will be responsive to trea2024
Monocyclic and bicyclic ring system substituted carbanucleoside analogues for us2024
Monocyclic and bicyclic ring system substituted carbanucleoside analogues for us2024
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inh2024
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inh2024
Spirobicyclic analogues2023
Methods of treating cancer using PRMT5 inhibitors2023
6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inh2022